AAAAAA

   
Results: 1-15 |
Results: 15
Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere) chemotherapy
Authors: Plunkett, TA Hanby, AM Miles, DW Rubens, RD
Citation: Ta. Plunkett et al., Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere) chemotherapy, ANN ONCOL, 12(3), 2001, pp. 411-414
Risk of complications from bone metastases in breast cancer: implications for management
Authors: Plunkett, TA Smith, P Rubens, RD
Citation: Ta. Plunkett et al., Risk of complications from bone metastases in breast cancer: implications for management, EUR J CANC, 36(4), 2000, pp. 476-482
Bone metastases - incidence and complications
Authors: Rubens, RD
Citation: Rd. Rubens, Bone metastases - incidence and complications, CANCER AND THE SKELETON, 2000, pp. 33-42
Bone metastases - general approaches to systemic treatment
Authors: Rubens, RD
Citation: Rd. Rubens, Bone metastases - general approaches to systemic treatment, CANCER AND THE SKELETON, 2000, pp. 151-158
Clinical aspects of bone metastases
Authors: Rubens, RD
Citation: Rd. Rubens, Clinical aspects of bone metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 85-96
The biology and management of bone metastases
Authors: Plunkett, TA Rubens, RD
Citation: Ta. Plunkett et Rd. Rubens, The biology and management of bone metastases, CR R ONC H, 31(1), 1999, pp. 89-96
Untitled
Authors: Coleman, RE Rubens, RD
Citation: Re. Coleman et Rd. Rubens, Untitled, CANC TR REV, 25(6), 1999, pp. 321-321
Twenty-five years of reviewing cancer treatment
Authors: Rubens, RD Coleman, RE
Citation: Rd. Rubens et Re. Coleman, Twenty-five years of reviewing cancer treatment, CANC TR REV, 25(1), 1999, pp. 1-2
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
Authors: Houston, SJ Plunkett, TA Barnes, DM Smith, P Rubens, RD Miles, DW
Citation: Sj. Houston et al., Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer, BR J CANC, 79(7-8), 1999, pp. 1220-1226
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer
Authors: Richards, MA Smith, P Ramirez, AJ Fentiman, IS Rubens, RD
Citation: Ma. Richards et al., The influence on survival of delay in the presentation and treatment of symptomatic breast cancer, BR J CANC, 79(5-6), 1999, pp. 858-864
Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients
Authors: Ahmad, A Barrington, S Maisey, M Rubens, RD
Citation: A. Ahmad et al., Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients, BR J CANC, 79(3-4), 1999, pp. 478-482
Taxoids - cost and benefit in the treatment of advanced breast cancer
Authors: Rubens, RD
Citation: Rd. Rubens, Taxoids - cost and benefit in the treatment of advanced breast cancer, CHALLENGES IN BREAST CANCER, 1999, pp. 213-220
What is the preferred second-line endocrine treatment in metastatic breastcancer?
Authors: Rubens, RD
Citation: Rd. Rubens, What is the preferred second-line endocrine treatment in metastatic breastcancer?, CHALLENGES IN BREAST CANCER, 1999, pp. 253-260
Current use of bisphosphonates in oncology
Authors: Body, JJ Bartl, R Burckhardt, P Delmas, PD Diel, IJ Fleisch, H Kanis, JA Kyle, RA Mundy, GR Paterson, AHG Rubens, RD
Citation: Jj. Body et al., Current use of bisphosphonates in oncology, J CL ONCOL, 16(12), 1998, pp. 3890-3899
Time trends in breast cancer survival: experience in a single centre, 1975-89
Authors: Bradburn, MJ Altman, DG Smith, P Fentiman, IS Rubens, RD
Citation: Mj. Bradburn et al., Time trends in breast cancer survival: experience in a single centre, 1975-89, BR J CANC, 77(11), 1998, pp. 1944-1949
Risultati: 1-15 |